ARTICLE | Company News

CHMP reviewing biosimilar Enbrel

January 17, 2015 4:39 AM UTC

EMA said it is reviewing an application for a biosimilar version of Enbrel etanercept, though the agency did not disclose which company submitted the application. Enbrel is a recombinant p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1 (TNFr:Fc).

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) has a biosimilar Enbrel in a Phase III trial for plaque psoriasis. The company declined to disclose details on its biosimilar. ...